Cyclic Peptide R10 CTLA-4 Binding Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immune checkpoint inhibitors, such as monoclonal antibodies, are not effective in all patients and there is a need for new therapies that can specifically target the CTLA-4 protein to enhance antitumor immune responses.
Innovation Solution
Development of cyclic peptide immune checkpoint inhibitors, specifically the R10 peptide (EIDTVLTPTGWVAKRYS), which binds to the CTLA-4 protein, blocking its association with CD80 and CD86 proteins, thereby activating the immune response against cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used as immune checkpoint inhibitors, then the immune response can be activated, but the therapy is not effective in all patients and lacks specificity
Solution Approach 1:
The cyclic peptide R10 is designed with specific local structural features (cyclic conformation, specific amino acid sequence) that provide high affinity and specificity for CTLA-4 binding, unlike conventional monoclonal antibodies that have more generalized binding characteristics. This localized structural optimization enables selective targeting of CTLA-4 with enhanced effectiveness.
Solution Approach 2:
The invention changes the molecular parameters from large monoclonal antibodies to small cyclic peptides, altering binding kinetics, tissue penetration, and immunogenicity characteristics. The cyclic peptide structure with specific molecular weight and conformation provides different pharmacological parameters that improve therapeutic effectiveness and patient response consistency.
2Productivity
If conventional immune checkpoint inhibitors are used, then T-cell activation can be stimulated, but the mechanism of action is not fully understood and efficacy varies
Solution Approach 1:
The cyclic peptide R10 is designed as a simplified copy or mimic of the B7-2 binding interface, capturing the essential binding features needed for CTLA-4 inhibition. This reduced-copy approach provides a more tractable system for mechanistic studies while maintaining therapeutic activity, enabling better understanding of the inhibition mechanism.
3Reliability
If new therapies are developed to specifically target CTLA-4, then antitumor immune responses can be enhanced, but the complexity of peptide design and synthesis increases
Solution Approach 1:
The complex CTLA-4 binding interface is segmented into a smaller, focused cyclic peptide structure that captures only the essential binding elements. This segmentation reduces the overall complexity from full monoclonal antibody structure to a minimal cyclic peptide (R10) that retains specific CTLA-4 targeting capability.
Solution Approach 2:
The cyclic peptide R10 combines specific amino acid residues in a cyclic conformation to create a composite structure with optimized binding properties. The cyclic structure itself acts as a composite feature that provides both structural stability and specific molecular recognition capabilities for CTLA-4.
Data Source
AI summary
Cancer immunotherapies comprising synthetic oligopep-tide-based immune checkpoint inhibitors, methods of treating cancers using the same, and kits and compositions for treatment.